MedTrace Logo

Dermatomyositis and Polymyositis Registry

NCT01637064 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2015-11-06

No results posted yet for this study

Summary

By creating a registry, physicians will have the opportunity to understand the clinical outcomes of Myositis patients treated with Acthar. Despite the availability of clinical exams, muscle biopsies, and other testing, it is surmised that there may be a more important classification of myositis that physicians are not diagnosing which could possibly lead to improper treatment due to inaccurate diagnosis. There may be several types of immune and inflammatory myositis (IIM) that do not fit well into the typical sub classifications of myositis.

Conditions

  • Dermatomyositis
  • Polymyositis

Interventions

DRUG

Acthar

Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.

Sponsors & Collaborators

  • Phoenix Neurological Associates, LTD

    lead OTHER

Principal Investigators

  • Todd D Levine, MD · Phoenix Neurological Associates, LTD

  • Petros Efthimiou, MD · New York Presbyterian Brooklyn Methodist Hospital

  • Ara Dikranian, MD · Ara Dikranian MD

  • Justine Malone, MD · Neurology INC

  • Rup Tandan, MD · University of Vermont

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01637064 on ClinicalTrials.gov